Carla Sayed

Carla Sayed is currently the Hospital Affairs Lead at Rhythm Pharmaceuticals Inc., where they oversee the launch of setmelanotide (Imcivree) for rare genetic obesity. Previously, they worked as a Key Account Manager for rare diseases at Amicus Therapeutics, promoting migalastat (Galafold) for Fabry disease. Carla has also held roles at Pierre Fabre Group as an Assistant Project Manager in medical marketing and as a Brand Representative at Hollister Co. They earned a Doctorate in Pharmacy from Université de Bourgogne and a Master’s in Management and Marketing of Health Industries from Toulouse Business School.